Obesity Trial, Recruiting
Who may be able to join
AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI
Who might be able to join this trial:
- People with a BMI between 30 and 38 (the obese group) or a BMI between 19 and 25 (the lean group)
Who may not be able to join:
- People who have been pregnant or breastfeeding in the past six months
- People who have Type 1 or Type 2 diabetes, or whose blood sugar or related test results are at levels that indicate diabetes
- People who have a history of liver disease, or whose liver enzyme levels from blood tests are more than twice the normal range
- People whose fasting triglyceride (a type of fat in the blood) levels are above 300 mg/dL, or whose total cholesterol is unusually high for their age and sex
- People whose haemoglobin or haematocrit levels (measures of red blood cells) fall below certain thresholds (confirm with trial site)
- People who have been diagnosed with HIV, hepatitis B, or hepatitis C
- People with a history of cancer (other than certain minor skin cancers), kidney disease at stage 3 or higher, or who are currently on dialysis
- People who have used diabetes medications or cholesterol-lowering medications in the past six months
- People who have had surgery for obesity
- People whose body weight has changed by more than 5% in the past six months (based on self-reported information)
- People with certain conditions known to affect how the body processes insulin or fats — such as polycystic ovary syndrome — or who have a history of galactosemia, hereditary fructose intolerance, or who test positive for difficulty absorbing fructose at the screening stage
- People with a known intolerance to acetaminophen (also known as paracetamol)
Important: Always verify eligibility with the trial site directly before applying.
Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.
Contact this trial
Principal Investigator: Jean-Marc Schwarz, PhD, Touro University, California
Phone: 707-638-5404
Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.
GP referral letter
Print a one-page summary to share with your doctor.
Trial details
Where this trial is recruiting
Primary endpoints
Fru-GNG; Fru-hGNG; Fru-iGNG; De novo lipogenesis (DNL)
Can't join this trial?
Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.